Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameBoard of Scientific Counselors Office of Infectious DiseasesAgency NameDepartment of Health and Human Services
Fiscal Year2019Committee Number812
Original Establishment Date11/17/1962Committee StatusChartered
Actual Termination Date Committee URLhttps://www.cdc.gov/ddid/BSC.html
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*30
Current Charter Date10/31/2017Designated Fed Officer Position Title*Senior Advisor to the Deputy Director for Infectious Diseases, CDC
Date Of Renewal Charter10/31/2019Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Sarah
Exempt From Renewal*NoDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*Wiley
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixMPH
Specific Establishment Authority*42 U.S.C. 217aDesignated Federal Officer Phone*(404) 639-4840
Effective Date Of Authority*11/17/1962Designated Federal Officer Fax*404-235-0511
Committee Type*ContinuingDesignated Federal Officer Email*swiley@cdc.gov
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Board provides critical advice and direction to the Secretary, Department of Health and Human Services (HHS); the CDC Office of the Director; the Deputy Director for Infectious Diseases; and the infectious disease national centers on improving the Agency’s efforts to prevent and control infectious diseases. The Board comprises a highly respected and diverse group of nationally and internationally recognized experts, who bring extensive experience to help CDC ensure sound public health policies and programmatic balance for current and emerging infectious disease threats. Their candid advice and critiques help to improve program focus and maximize program effectiveness. Throughout the years, the Board has provided valuable advice to CDC for strengthening public health capacity at the national, state, and local levels; enhancing preparedness to address new diseases and public health challenges; developing new tools for detecting and controlling infectious diseases; and implementing science-based programs to prevent the spread of infectious diseases. The Board's global scientific expertise plays an integral role in helping CDC's infectious disease programs stay abreast of current health trends and appropriate scientific directions, thereby ensuring the highest quality prevention and control efforts.
How is membership balanced?*The Board consists of 17 public members, including the Chair. Members are selected by the Secretary from authorities knowledgeable in the fields relevant to the issues addressed by the infectious disease national centers (e.g., respiratory diseases, healthcare-associated infections, antimicrobial resistance, foodborne diseases, zoonotic and vector-borne diseases, sexually transmitted diseases, preparedness) and related specialties, including clinical and public health practice (including state and local health departments), laboratory practice, research, diagnostics, microbiology, immunology, molecular biology, bioinformatics, health policy/communications, and industry. The Board provides the expertise to help strengthen these disciplines and the scientific validity of CDC's infectious disease programs. In addition to the broad professional expertise, a diverse membership, including the geographical location of members, helps to ensure that the committee provides a well-balanced perspective.
How frequent & relevant are cmte mtgs?*The full Board convened twice in FY 2019 through one in-person, 2-day meeting and one half-day teleconference. Between meetings, the Board is kept abreast of CDC’s infectious disease activities through periodic emails and informational calls. In addition, the Board’s four workgroups convened in FY 2019 as follows: The Food Safety Modernization Act (FSMA) Surveillance Working Group met three times through two in-person, 2-day meetings and one teleconference; the Infectious Disease (ID) Laboratory Working Group met once through a teleconference; the Vector-borne Diseases (VBD) Workgroup of the BSC/OID and the Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry, met three times through teleconferences; and the newly formed Acute Flaccid Myelitis (AFM) Task Force met 10 times through one in-person, 1-day meeting, one in-person, 2-day meeting, and eight teleconferences. The efforts of the full Board and its workgroups in updating and prioritizing goals and directions to meet both ongoing and evolving public health needs for infectious diseases are critical to national and global health. An important component of the activities of the Board and its workgroups is ensuring that the public health, clinical, and research communities are aware of and focused on changing health challenges and priorities. The Board’s advice is extremely beneficial to the CDC Director; the Deputy Director for Infectious Diseases; the Directors of the infectious disease national centers; and the scientists and managers within the programs. Examples of the Board’s activities over the past fiscal year include providing information and advice to 1) help advance CDC’s priority activities to end the HIV epidemic; 2) help advance CDC’s efforts to address the U.S. opioid epidemic, including reducing infections associated with opioid use; 3) help advance CDC efforts to reduce antimicrobial resistance, including actions outlined by the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria; 4) address, beyond what CDC can do alone, antibiotic resistance in countries where antibiotics can be purchased without a prescription; 5) help CDC develop its plan for implementing strategy for vector-borne disease prevention and control in the United States, as well as guide CDC on which priority activities to include in the CDC Action Plan for Vector-Borne Disease Prevention and Control in the United States; 6) help advance CDC’s efforts to address an increase in the number of cases of AFM since national investigation began in 2014, including efforts to provide considerations on clinical management of the disease; 7) help advance CDC’s efforts to improve screening for and prevention of STDs; 8) help advance CDC’s efforts to encourage travelers to protect themselves from malaria and other infectious diseases; and 9) help CDC advance global laboratory biosafety and biosecurity. Examples of advice given to the HHS Secretary over the past fiscal year include 1) recommendations regarding the improvement of foodborne illness surveillance, and 2) a recommendation for action regarding a conditions-of-participation rule proposed by the Centers for Medicare and Medicaid Services to implement antibiotic stewardship programs in hospitals.

The Board also provided comments on action steps proposed by its workgroups. The FMSA Surveillance Working Group is charged with providing input to CDC, the U.S. Food and Drug Administration (FDA), and HHS (e.g., through the BSC/OID) on ways to enhance foodborne illness surveillance. Examples of the group’s work during FY 2019 include providing input to the Board on 1) CDC foodborne illness surveillance data systems and strategies; 2) the activities and analytic approaches of the Interagency Food Safety Analytics Collaboration (IFSAC), a partnership between CDC, FDA, and the Food Safety and Inspection Service of the United States Department of Agriculture; 3) recent significant produce outbreaks; 4) challenges and opportunities of whole genome sequencing (WGS) for illness detection and response; and 5) water as a food safety program. The ID Laboratory Working Group helps the Board guide CDC’s efforts in incorporating the use of new molecular detection tools and computing technologies into public health, ensuring that public health laboratories have access to state-of-the-art technologies for detecting and preventing infectious disease threats. Over the past fiscal year, the group reviewed the ongoing progress and accomplishments of CDC’s advanced molecular detection (AMD) program and priorities for moving forward, while beginning to shift the group’s focus toward CDC’s strategy for addressing the use of culture-independent diagnostic tests (CIDTs) in clinical settings but continuing to review the ongoing progress of the AMD program. The joint VBD Workgroup was established in FY 2018 to ensure broad external input on the diverse and complex issues involved in the prevention and control of VBDs. In FY 2019, the group focused on two issues: 1) reviewing the responsibilities and strategies of the current VBD programs in two of CDC/ATSDR’s national centers and addressing efforts to coordinate activities between the centers, and 2) reviewing the vector-borne disease prevention and control in the United States and providing input to the Board into strategies to further the prevention of vector-borne diseases. The AFM Task Force was established early in FY 2019 to aid in the ongoing investigation to define the cause of, and improve treatment and outcomes for, patients with AFM. This fiscal year, the group shared findings, observations, and outcomes with the full Board in two key areas: 1) AFM etiologies and pathogenesis, and 2) clinical treatment of AFM. The workgroup has also identified gaps in knowledge related to pathogenesis and clinical management of AFM and has been discussing potential studies and evaluations that could address these gaps, as well as how these research activities should be prioritized.
Why advice can't be obtained elsewhere?*The Board plays an essential role in assisting CDC and the infectious disease national centers in evaluating programs, setting priorities, and developing and achieving goals. Over this next year, the Board and its workgroups will play an important role in helping CDC address several critical public health issues. Examples include identifying and implementing short- and long-term public health actions needed to prevent surveillance gaps, particularly regarding surveillance for foodborne illnesses, as the use of molecular detection capacities expand; advancing national and global strategies to control antimicrobial resistance and reduce healthcare-associated infections; advancing CDC’s efforts to develop and train the next generation of infectious disease public health workers, including efforts to maintain the Epidemic Intelligence Service and efforts to address, with other federal agencies, workforce development issues in vector-borne disease control; and considering various mechanisms and strategies to provide optimal health recommendations for travelers. The Board and its workgroups have significant expertise in these areas that can help CDC best focus resources strategically. The broad infectious disease expertise represented on the Board and centralized in one committee does not exist elsewhere.
Why close or partially close meetings?N/A
Recommendation RemarksNo formal reports from the full Board are required; the Board provides advice and recommendations through various means other than formal reports. The Food Safety Modernization Act (FSMA) Surveillance Working Group of the BSC/OID is required by FSMA to submit annual reports to the HHS Secretary and does so through the Board. Terms for five Board members ended in FY 2018. Board Chair Ruth Lyon Berkelman and member Michael T. Brady, Special Government Employees, completed their terms on the Board on March 31, 2018. John E. Bennett, one of the two ex officio members from the National Institutes of Health, ended his term on the Board on December 20, 2017. Melinda Wharton, the ex officio member from the National Vaccine Program Office (NVPO), ended her term on the Board on August 24, 2018, at the end of her detail as Acting NVPO Director. Theresa Tam, liaison representative from the Public Health Agency of Canada, ended her term on the Board on February 1, 2018.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryYesAction OtherNo
Outcome Increased Customer SatisfactionYesAction CommentN/A
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentN/ANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentThe Board’s advice and guidance to CDC’s infectious disease programs could impact cost savings in numerous ways. Through their broad expertise, the members help identify new strategies and opportunities to better target and focus prevention and control efforts, including strengthening existing and building new public-private partnerships. The Board has also been instrumental in helping enhance collaborations across federal organizations, leading to improved responses as well as decreased overlap.Grants Review CommentN/A
Number Of Recommendations*180Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentRecommendations were made to CDC leadership and staff during meetings and through meeting reports, and to the HHS Secretary through the FSMA Surveillance Working Group’s annual report and via a letter supporting a Centers for Medicare and Medicaid Services proposal to implement new antibiotic stewardship standards in acute care hospitals. Examples of informal recommendations and individual comments provided during FY 2019 include the need for CDC to 1) consider expanded roles for the Emerging Infections Program sites, the National Healthcare Safety Network, the Antibiotic Resistance Laboratory Network, and others to enhance systematic surveillance for invasive bacterial and fungal infections and syndromes among persons who inject drugs; 2) work with other federal agencies to address priority, cross-cutting issues outlined in agency-specific action plans to forward vector-borne disease prevention and control in the United States; 3) strengthen public health capacity to analyze large, complex data sources like whole genome sequencing; 4) enhance information and resources for travelers regarding travel vaccines and prophylactic treatments; 5) engage vendors of electronic records used by acute and long-term care healthcare facilities regarding public health needs; 6) establish strong research collaborations to address Acute Flaccid Myelitis, advance knowledge base, and strengthen education and communication outreach on this important public health issue; and 7) through the Infectious Disease Laboratory Working Group, further explore issues on culture-independent diagnostic testing (CIDT).Access Agency WebsiteYes
% of Recs Fully Implemented*30.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe joint vector-borne diseases (VBDs) working group, which reports to both the OID and the NCEH/ATSDR Boards of Scientific Counselors, reviewed strategic plans and activities of relevant groups in both programs. Based on the working group’s findings, the BSC recommended specific identification of opportunities for collaboration between the Division of Vector-Borne Diseases and the National Center for Environmental Health. The two programs have done this, and have addressed common areas including training, collaboration with state partners, and agency-wide input to the vector-borne disease prevention and control. The charge of the Infectious Disease Laboratory Working Group has been updated to include focus on reviewing CDC’s overall strategy for addressing the impact of CIDTs in clinical settings, and the working group will address this at its next meeting.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*60.00%Access PublicationsYes
% of Recs Partially Implemented CommentRecommendations and advice regarding vendors of electronic records and public health are underway, via the Digital Bridge, a forum for decision-makers across sectors to develop a nationally consistent and sustainable approach to using electronic health data. Recommendations regarding better understanding the natural history and progression of Acute Flaccid Myelitis are also underway, via interagency collaborations, case-series investigations, and clinical information abstractions, among other methods.Access OtherNo
Agency Feedback*YesAccess CommentThe full minutes of each Board meeting, which includes summaries of workgroup meetings, are posted on CDC's website.
Agency Feedback CommentAt each Board meeting, CDC staff and leadership provide updates on previous recommendations received from the full Board or suggestions from individual Board members and from the working groups. Feedback is also provided less formally via email updates. Recommendations and suggestions by Board members are also regularly categorized and presented to CDC leadership.Narrative Description*The full Board convened twice in FY 2019 through one in-person, 2-day meeting and one half-day teleconference. Between meetings, the Board is kept abreast of CDC’s infectious disease activities through periodic emails and informational calls. In addition, the Board’s four workgroups convened in FY 2019 as follows: The Food Safety Modernization Act (FSMA) Surveillance Working Group met three times through two in-person, 2-day meetings and one teleconference; the Infectious Disease (ID) Laboratory Working Group met once through a teleconference; the Vector-borne Diseases (VBD) Workgroup of the BSC/OID and the Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry, met three times through teleconferences; and the newly formed Acute Flaccid Myelitis (AFM) Task Force met 10 times through one in-person, 1-day meeting, one in-person, 2-day meeting, and eight teleconferences. The efforts of the full Board and its workgroups in updating and prioritizing goals and directions to meet both ongoing and evolving public health needs for infectious diseases are critical to national and global health. An important component of the activities of the Board and its workgroups is ensuring that the public health, clinical, and research communities are aware of and focused on changing health challenges and priorities. The Board’s advice is extremely beneficial to the CDC Director; the Deputy Director for Infectious Diseases; the Directors of the infectious disease national centers; and the scientists and managers within the programs. Examples of the Board’s activities over the past fiscal year include providing information and advice to 1) help advance CDC’s priority activities to end the HIV epidemic; 2) help advance CDC’s efforts to address the U.S. opioid epidemic, including reducing infections associated with opioid use; 3) help advance CDC efforts to reduce antimicrobial resistance, including actions outlined by the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria; 4) address, beyond what CDC can do alone, antibiotic resistance in countries where antibiotics can be purchased without a prescription; 5) help CDC develop its plan for implementing strategy for vector-borne disease prevention and control in the United States, as well as guide CDC on which priority activities to include in the CDC Action Plan for Vector-Borne Disease Prevention and Control in the United States; 6) help advance CDC’s efforts to address an increase in the number of cases of AFM since national investigation began in 2014, including efforts to provide considerations on clinical management of the disease; 7) help advance CDC’s efforts to improve screening for and prevention of STDs; 8) help advance CDC’s efforts to encourage travelers to protect themselves from malaria and other infectious diseases; and 9) help CDC advance global laboratory biosafety and biosecurity. Examples of advice given to the HHS Secretary over the past fiscal year include 1) recommendations regarding the improvement of foodborne illness surveillance, and 2) a recommendation for action regarding a conditions-of-participation rule proposed by the Centers for Medicare and Medicaid Services to implement antibiotic stewardship programs in hospitals.

The Board also provided comments on action steps proposed by its workgroups. The FMSA Surveillance Working Group is charged with providing input to CDC, the U.S. Food and Drug Administration (FDA), and HHS (e.g., through the BSC/OID) on ways to enhance foodborne illness surveillance. Examples of the group’s work during FY 2019 include providing input to the Board on 1) CDC foodborne illness surveillance data systems and strategies; 2) the activities and analytic approaches of the Interagency Food Safety Analytics Collaboration (IFSAC), a partnership between CDC, FDA, and the Food Safety and Inspection Service of the United States Department of Agriculture; 3) recent significant produce outbreaks; 4) challenges and opportunities of whole genome sequencing (WGS) for illness detection and response; and 5) water as a food safety program. The ID Laboratory Working Group helps the Board guide CDC’s efforts in incorporating the use of new molecular detection tools and computing technologies into public health, ensuring that public health laboratories have access to state-of-the-art technologies for detecting and preventing infectious disease threats. Over the past fiscal year, the group reviewed the ongoing progress and accomplishments of CDC’s advanced molecular detection (AMD) program and priorities for moving forward, while beginning to shift the group’s focus toward CDC’s strategy for addressing the use of culture-independent diagnostic tests (CIDTs) in clinical settings but continuing to review the ongoing progress of the AMD program. The joint VBD Workgroup was established in FY 2018 to ensure broad external input on the diverse and complex issues involved in the prevention and control of VBDs. In FY 2019, the group focused on two issues: 1) reviewing the responsibilities and strategies of the current VBD programs in two of CDC/ATSDR’s national centers and addressing efforts to coordinate activities between the centers, and 2) reviewing the vector-borne disease prevention and control in the United States and providing input to the Board into strategies to further the prevention of vector-borne diseases. The AFM Task Force was established early in FY 2019 to aid in the ongoing investigation to define the cause of, and improve treatment and outcomes for, patients with AFM. This fiscal year, the group shared findings, observations, and outcomes with the full Board in two key areas: 1) AFM etiologies and pathogenesis, and 2) clinical treatment of AFM. The workgroup has also identified gaps in knowledge related to pathogenesis and clinical management of AFM and has been discussing potential studies and evaluations that could address these gaps, as well as how these research activities should be prioritized.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members* Est Payments to Non-Fed Members Next FY* 
Payments to Federal Members* Est. Payments to Fed Members Next FY* 
Payments to Federal Staff* Estimated Payments to Federal Staff* 
Payments to Consultants* Est. Payments to Consultants Next FY* 
Travel Reimb. For Non-Federal Members* Est Travel Reimb Non-Fed Members nextFY* 
Travel Reimb. For Federal Members* Est Travel Reimb For Fed Members* 
Travel Reimb. For Federal Staff* Est. Travel Reimb to Fed Staff Next FY* 
Travel Reimb. For Consultants* Est Travel Reimb to Consultants Next FY* 
Other Costs Est. Other Costs Next FY* 
Total Costs$0.00Est. Total Next FY*$0.00
Federal Staff Support (FTE)* Est. Fed Staff Support Next FY* 
Hide Section - Custom Links

Custom Links

     Committee Level Reports               
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-001951Board of Scientific Counselors Office of Infectious Diseases2017
 COM-002228Board of Scientific Counselors Office of Infectious Diseases2016
 COM-004150Board of Scientific Counselors Office of Infectious Diseases2015
 COM-004549Board of Scientific Counselors Office of Infectious Diseases2014
 COM-006143Board of Scientific Counselors Office of Infectious Diseases2013
 COM-006866Board of Scientific Counselors Office of Infectious Diseases2012
 COM-008336Board of Scientific Counselors Office of Infectious Diseases2011
 COM-009065Board of Scientific Counselors Office of Infectious Diseases2010
 COM-010212Board of Scientific Counselors Coordinating Center for Infectious Diseases2009
 COM-010986Board of Scientific Counselors Coordinating Center for Infectious Diseases2008
 COM-012220Board of Scientific Counselors Coordinating Center for Infectious Diseases2007
 COM-012549Board of Scientific Counselors, National Center for Infectious Diseases2006
 COM-013722Board of Scientific Counselors, National Center for Infectious Diseases2005
 COM-014783Board of Scientific Counselors, National Center for Infectious Diseases2004
 COM-016003Board of Scientific Counselors, National Center for Infectious Diseases2003
 COM-016505Board of Scientific Counselors, National Center for Infectious Diseases2002
 COM-017961Board of Scientific Counselors, National Center for Infectious Diseases2001
 COM-018689Board of Scientific Counselors, National Center for Infectious Diseases2000
 COM-019767Board of Scientific Counselors, National Center for Infectious Diseases1999
 COM-020643Board of Scientific Counselors, National Center for Infectious Diseases1998
 COM-021469Board of Scientific Counselors, National Center for Infectious Diseases1997
 COM-034869Board of Scientific Counselors Office of Infectious Diseases2018